Team:UFMG Brazil/Cardbio
From 2013.igem.org
(Difference between revisions)
(→The Problem) |
(→The Problem) |
||
Line 7: | Line 7: | ||
[[File:cardbio_problem_graph2.jpg|400px|thumb|center|Figure 2. The 10 leading causes of death in the world at 2011 (World Health Organization, July 2013)]] | [[File:cardbio_problem_graph2.jpg|400px|thumb|center|Figure 2. The 10 leading causes of death in the world at 2011 (World Health Organization, July 2013)]] | ||
- | It is observed in ACS that plaque formation and its development release several substances in the patient blood that have a big potential to be explored as possible biomarkers for diagnosis of ACS | + | It is observed in ACS that plaque formation and its development release several substances in the patient blood that have a big potential to be explored as possible biomarkers for diagnosis of ACS. In this context, several biomarkers are described to pathophysiological processes associated with acute myocardial infarction as shown in the Figure 2. |
[[File:cardbio_problem_graph3.jpg|700px|thumb|center|Figure 3 - Biomarkers associated with various pathophysiological processes associated with acute myocardial infarction[referencia]]] | [[File:cardbio_problem_graph3.jpg|700px|thumb|center|Figure 3 - Biomarkers associated with various pathophysiological processes associated with acute myocardial infarction[referencia]]] | ||
- | Given these information, Brazil_UFMG team chose to develop a Genetically Modified Organism (GMO) able to measure blood serum concentrations of specific molecules with potential to be ACS biomarkers | + | Given these information, Brazil_UFMG team chose to develop a Genetically Modified Organism (GMO) able to measure blood serum concentrations of specific molecules with potential to be ACS biomarkers and to be used as an efficient method of prognostic test for this syndrome. |
'''References:''' | '''References:''' |
Revision as of 21:15, 27 September 2013